
Adding a newer drug to standard hormone therapy lengthens the lives of younger women with advanced breast cancer, a new trial has found. The drug, called Kisqali (ribociclib), is already approved for treating such patients — based on earlier results showing it can delay the progression of their cancer. This is the first evidence it… read on >